Preclinical and clinical studies have shown sensitivity of PARP inhibitors and venetoclax in resistant CML cell lines by inhibiting the error-prone alternate NHEJ pathway; further clinical development is under way for CML [97]. This evidence concerns the gene PARP1 and chronic myelogenous leukemia, BCR-ABL1 positive.